Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial

OBJECTIVE: To report the 2‐year efficacy and safety of tocilizumab (TCZ) in patients with polyarticular‐course juvenile idiopathic arthritis (JIA). METHODS: Patients ages 2–17 years with active polyarticular‐course JIA, in whom treatment with methotrexate was unsuccessful, received 16 weeks of open‐...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Arthritis Rheumatol
Autori principali: Brunner, Hermine I., Ruperto, Nicolino, Zuber, Zbigniew, Cuttica, Rubén, Keltsev, Vladimir, Xavier, Ricardo M., Burgos‐Vargas, Ruben, Penades, Inmaculada Calvo, Silverman, Earl D., Espada, Graciela, Zavaler, Manuel Ferrandiz, Kimura, Yukiko, Duarte, Carolina, Job‐Deslandre, Chantal, Joos, Rik, Douglass, Wendy, Wimalasundera, Sunethra, Bharucha, Kamal N., Wells, Chris, Lovell, Daniel J., Martini, Alberto, de Benedetti, Fabrizio
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
Pediatric Rheumatology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7986602/
https://ncbi.nlm.nih.gov/pubmed/32951358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41528
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi